Take a closer look at how erenumab, the first CGRP inhibitor to win FDA-approval for migraine prevention, earned that spot.
References:1. FDA.Â FDA approves novel preventive treatment for migraine. May 2018. Accessed May 31 2018 at: https://www.fda.gov/NewsEvents/Newsroom/PressAnnouncements/ucm608120.htmÂ 2.Â 2. Dodick DW, Ashina M, Brandes JL, et al. ARISE: A Phase 3 randomized trial of erenumab for episodic migraine. Cephalalgia. 2018;38:1026-1037.Â 3.Â 3. Lipton RB, Brennan A, Palmer S, et al. Estimating the clinical effectiveness and value-based price range of erenumab for the prevention of migraine in patients with prior treatment failures: a US societal perspective. J Med Econ. 2018;3:1-10Â Â